GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Cash Ratio

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Cash Ratio : 0.01 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Bellevue Life Sciences Acquisition's Cash Ratio for the quarter that ended in Dec. 2023 was 0.01.

Bellevue Life Sciences Acquisition has a Cash Ratio of 0.01. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Bellevue Life Sciences Acquisition's Cash Ratio or its related term are showing as below:

BLAC' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.06   Max: 0.2
Current: 0.01

During the past 4 years, Bellevue Life Sciences Acquisition's highest Cash Ratio was 0.20. The lowest was 0.01. And the median was 0.06.

BLAC's Cash Ratio is ranked worse than
89.66% of 464 companies
in the Diversified Financial Services industry
Industry Median: 0.945 vs BLAC: 0.01

Bellevue Life Sciences Acquisition Cash Ratio Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Cash Ratio Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Ratio
0.20 0.01 0.10 0.01

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.10 0.87 - 0.05 0.01

Competitive Comparison of Bellevue Life Sciences Acquisition's Cash Ratio

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellevue Life Sciences Acquisition's Cash Ratio Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's Cash Ratio falls into.



Bellevue Life Sciences Acquisition Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Bellevue Life Sciences Acquisition's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.015/2.038
=0.01

Bellevue Life Sciences Acquisition's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.015/2.038
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellevue Life Sciences Acquisition  (NAS:BLAC) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Bellevue Life Sciences Acquisition Cash Ratio Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004